Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Gilead Collaborates With Pfizer For Yescarta Combo Study

By Zacks Investment ResearchStock MarketsJan 19, 2018 05:35AM ET
www.investing.com/analysis/gilead-collaborates-with-pfizer-for-yescarta-combo-study-200281949
Gilead Collaborates With Pfizer For Yescarta Combo Study
By Zacks Investment Research   |  Jan 19, 2018 05:35AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Gilead Sciences’ (NASDAQ:GILD) subsidiary Kite announced that it has entered into a collaboration with Pfizer, Inc. (NYSE:PFE) to evaluate a combination of its newly approved CAR-T therapy Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a 4-1BB agonist, for refractory large B-cell lymphoma.

A phase I/II study is expected to begin in 2018 and will be sponsored by Kite. The results of the study will be used to find options for further development of this combination, or similar combinations between Kite’s engineered T-cell products and utomilumab.

Gilead’s stock has increased 13.4% in the year so far, compared with the industry’s 3.8% gain.

Yescarta was approved in October 2017 as the second (CAR) T cell therapy to get FDA approval. The first CAR-T therapy — Novartis’ (NYSE:NVS) Kymriah received approval by the FDA in August 2017. Yescarta is the first CAR-T therapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Pfizer is developing utomilumab, also known as PF-05082566, in both hematologic cancers and solid tumors as a single agent and in combination with other anti-cancer therapies.

We remind investors that Kite was acquired by Gilead in October 2017. Kite was a pioneer in cell therapy, having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the type of cancer. The acquisition diversified Gilead’s portfolio and positioned the company in a dominant position in cellular therapy space.

The CAR-T therapy space has remained in investor focus in 2017, courtesy of immense potential. CAR-T cell therapy is expected to be revolutionary in cancer treatment.

Another company that also develops CAR-T therapy is Juno Therapeutics, Inc. (NASDAQ:JUNO) , whose most advanced pipeline candidates include JCAR017 and JCAR014. Juno was also in the news recently after reports surfaced that it will be acquired by Celgene Corporation (NASDAQ:CELG).

Another clinical-stage company committed to developing CAR-T therapy is bluebird bio, Inc., whose lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs which are being developed in collaboration with Celgene.

Zacks Rank

Gilead has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp (NYSE:FMC). and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >



Pfizer, Inc. (PFE): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report

Original post

Zacks Investment Research
Gilead Collaborates With Pfizer For Yescarta Combo Study
 

Related Articles

Tim Knight
Looming Ceilings For Some ETFs By Tim Knight - May 27, 2022

Ever since last week, the market has been slicing the heads off bears left and right, with the Dow up thousandsof points and the S&P 500 Futures up about 300. It’s been...

Gilead Collaborates With Pfizer For Yescarta Combo Study

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email